In vitro: DEM induces upregulation of GSH(L-c-glutamyl-L-cysteinyl-glycine) metabolism, and the downregulation of pathways of cancer, chemokine signaling, cytokine-cytokine receptor, and focal adhesion in transformed cells. DEM appears to modify microenvironment of transformed cells thereby restraining tumor cell growth. DEM is cytotoxic to the transformed cells in a concentration dependent manner. DEM at 0.25 mM decreases cell viability to 75%. The co-exposure of cells to DEM+GSHe inhibits DEM induced cytotoxicity. DEM exposure increases the ROS generation by multiple orders of magnitude in transformed cells. This is evident from the dose and time dependent increase in fluorescence intensity of CMH2DCFDA. Moreover, DEM activates MAPK pathway and DEM induced activation of ERK is found to be due to phosphorylation at Thr 202/204.
In vivo: Sperm motility and epididymal sperm count are significantly reduced in the DEM treated animals. Fertility status is also affected by DEM exposure as is evident from the percent fertility and the litter size. consequences of the oxidative stress produced by the DEM induces glutathione depletion, on the reproductive ability of male mice and modulation of the various components of the antioxidant defense system at the transcriptional level.
J Agric Food Chem. 2023 Dec 13;71(49):19465-19474.
CYP4CL2 Confers Metabolic Resistance to Pyridaben in the Citrus Pest Mite Panonychus citri
Diethylmaleate purchased from AbMole
| Cell Experiment | |
|---|---|
| Cell lines | Transformed cells (tC3H10T1/2 and tBALB/c) |
| Preparation method | A stock solution of DEM is prepared in 100% DMSO and diluted in DMEM to achieve the desired concentration with less than 0.1% DMSO in the culture wells. Briefly, cells are seeded (1 ×104 cells/well) in 96-well plates and allowed to adhere overnight. Subsequently, these cells are exposed to DEM at various test concentrations (0.05-1 mM) or co-exposed to equimolar (0.25 mM) DEM+GSHe for 24 h. Cell viability is determined by recording the OD at 570 nm in an Elisa microplate reader. |
| Concentrations | Various test concentrations (0.05-1 mM) |
| Incubation time | 24 h |
| Animal Experiment | |
|---|---|
| Animal models | Sprague-Dawley rats |
| Formulation | corn oil |
| Dosages | A range of doses up to a maximum of 6mmol/kg |
| Administration | i.p. |
| Molecular Weight | 172.18 |
| Formula | C8H12O4 |
| CAS Number | 141-05-9 |
| Form | Liquid |
| Solubility (25°C) | DMSO 90 mg/mL Soluble in Ethanol |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
| Related NF-κB Products |
|---|
| Narlumosbart
Narlumosbart is a human IgG4ҡ monoclonal antibody (mAb) that targets Receptor Activating Factor for Nuclear Factor κB Ligand (RANKL) and can be used in studies related to Giant Cell Tumor of Bone (GCTB). |
| Ac2-26
Ac2-26, an active N-terminal peptide of annexin A1 (AnxA1), attenuates ischemia-reperfusion-induced acute lung injury. |
| Mitogen-activated protein kinase 1
Mitogen-activated protein kinase 1 (MAPK1) can activate the downstream p38/NF-κB pathway. |
| IKKγ NBD Inhibitory Peptide
IKKγ NBD Inhibitory Peptide is a highly specific inhibitor NF-κB inhibitor. |
| Tripeptide-41
Tripeptide-41(CG-Lipoxyn)isa bioactive peptide withreduce fat accumulationeffect and has been reported used as a cosmetic ingredient. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
